PTC Therapeutics, Inc. Operating Cash Flow

Operating Cash Flow of PTCT for past 10 years: annual, quarterly and twelve month trailing (TTM) including Operating Cash Flow growth rates and interactive chart. Operating cash flow (OCF) is a measure of the amount of cash generated by a company's normal business operations. Operating cash flow indicates whether a company can generate sufficient positive cash flow to maintain and grow its operations, otherwise it may require external financing for expansion or even survival. A negative number means the company is funded through external capital (debt or equity issuance) or cash available on the balance sheet. A positive number means that a company generates enough cash to pay for its operations.


Highlights and Quick Summary

  • Operating Cash Flow for the quarter ending June 29, 2021 was $-31.1 Million (a -68.9% decrease compared to previous quarter)
  • Year-over-year quarterly Operating Cash Flow decreased by -216.83%
  • Annual Operating Cash Flow for 2020 was $-194 Million (a 96.75% increase from previous year)
  • Annual Operating Cash Flow for 2019 was $-98.6 Million (a 256.86% increase from previous year)
  • Annual Operating Cash Flow for 2018 was $-27.6 Million (a 174.68% increase from previous year)
  • Twelve month Operating Cash Flow ending June 29, 2021 was $-169 Million (a -20.53% decrease compared to previous quarter)
  • Twelve month trailing Operating Cash Flow increased by 20.8% year-over-year
Trailing Operating Cash Flow for the last four month:
29 Jun '21 30 Mar '21 30 Dec '20 29 Sep '20
$-169 Million $-213 Million $-194 Million $-140 Million
Visit stockrow.com/PTCT for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Operating Cash Flow of PTC Therapeutics, Inc.

Most recent Operating Cash Flowof PTCT including historical data for past 10 years.

Interactive Chart of Operating Cash Flow of PTC Therapeutics, Inc.

PTC Therapeutics, Inc. Operating Cash Flow for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 $-31.15 $-100.16
2020 $-64.37 $26.66 $-74.81 $-81.55 $-194.07
2019 $-10.21 $-15.5 $-30.52 $-42.41 $-98.64
2018 $-15.14 $3.38 $0.0 $-15.88 $-27.64
2017 $21.29 $-15.77 $13.32 $-28.9 $-10.06
2016 $-13.32 $-24.08 $-24.59 $-41.59 $-103.57
2015 $-30.33 $-27.76 $-29.82 $-36.43 $-124.34
2014 $-7.99 $-17.04 $-18.81 $-13.44 $-57.27
2013 $-14.46 $-5.18 $-19.44 $-7.85 $-46.92
2012 $-11.03 $-6.2 $-14.12 $-16.58 $-47.93
2011 $-20.76 $-20.77

Business Profile of PTC Therapeutics, Inc.

Sector: Healthcare
Industry: Biotechnology
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focuses on the development of treatments for multiple therapeutic areas, including rare diseases and oncology. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy in the European Economic Area and the United States; commercializes Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean; and markets Evrysdi for the treatment of SMA in adults and children two months and older in Brazil. The company's splicing platform includes PTC518, which is being developed for the treatment of Huntington's disease. PTC Therapeutics, Inc. has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., as well as the Spinal Muscular Atrophy Foundation to advance drug discovery and development research in regenerative medicine; research collaboration with Massachusetts General Hospital for the treatment of rare genetic disorders resulting from pre-mRNA; and Akcea Therapeutics, Inc. to commercialize Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean. PTC Therapeutics, Inc. was founded in 1998 and is headquartered in South Plainfield, New Jersey.